Spots Global Cancer Trial Database for busulfan
Every month we try and update this database with for busulfan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | NCT01823198 | Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related... | Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological... | 7 Years - 65 Years | M.D. Anderson Cancer Center | |
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | NCT00004128 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | NCT00070135 | Adult Acute Mye... Acute Myeloid L... | filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema... | 60 Years - 74 Years | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients | NCT02670109 | Triple-Negative... Residual Tumor | Carmustine Cyclophosphamid... Carboplatin Autologous Hema... Busulfan | 18 Years - 60 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT | NCT02670252 | Allogeneic Hema... Busulfan Total Body Irra... Acute Lymphocyt... | Busulfan (BU) Cyclophosphamid... Total Body Irra... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Phase II Trial of Pentostatin and Targeted Busulfan | NCT00496340 | Hematologic Mal... | Pentostatin Busulfan Rituximab Allogeneic Hema... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02057770 | Leukemia, Myelo... | busulfan fludarabine pho... total-body irra... Stem cell trans... cyclophosphamid... tocilizumab | 18 Years - | Washington University School of Medicine | |
| Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | NCT00005940 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... | iodine I 131 mo... busulfan cyclophosphamid... allogeneic bone... allogeneic hema... peripheral bloo... cyclosporine methotrexate laboratory biom... | 16 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | NCT03259503 | Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce... | Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL. | NCT02047578 | Acute Lymphobla... | Busulfan | - 21 Years | Seoul National University Hospital | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | NCT03602898 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related... | Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra... | - 65 Years | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma | NCT03794167 | Non-hodgkin Lym... | Busulfan Cyclophosphamid... Etoposide Melphalan | 18 Years - 65 Years | Soonchunhyang University Hospital | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission | NCT00002768 | Leukemia | filgrastim busulfan cytarabine etoposide methotrexate peripheral bloo... | 15 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma | NCT00003101 | Brain and Centr... | filgrastim busulfan lomustine procarbazine hy... thiotepa vincristine sul... autologous bone... peripheral bloo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | NCT01824693 | Juvenile Myelom... | Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Pharmacological... Tacrolimus | 3 Months - 18 Years | Children's Oncology Group | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission | NCT00667927 | Acute Myeloid L... | Busulfan Cyclophosphamid... Mesna | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study | NCT00156858 | Hematologic Mal... | intravenous bus... | - 70 Years | AHS Cancer Control Alberta | |
| Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia | NCT00550992 | Leukemia | anti-thymocyte ... asparaginase busulfan cyclophosphamid... cyclosporine cytarabine daunorubicin hy... etoposide leucovorin calc... melphalan mercaptopurine methotrexate mitoxantrone hy... pegaspargase prednisolone prednisone therapeutic hyd... thioguanine vincristine sul... allogeneic bone... allogeneic hema... umbilical cord ... | - 1 Year | Dutch Childhood Oncology Group | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies | NCT01435447 | Lymphoid Malign... | FLu-Bu-Cy | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | NCT00475020 | Myelofibrosis | Busulfan Fludarabine Thymoglobulin (... | - 75 Years | M.D. Anderson Cancer Center | |
| Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies | NCT02120157 | Myeloablative C... HLA-mismatched ... Graft Survival Transplantation... | Cyclophosphamid... TBI Busulfan Unmanipulated B... Tacrolimus Mycophenolate m... | 6 Months - 25 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma | NCT04690192 | Large B-cell Ly... | CNCT19 Gemcitabine Inj... busulfan Melphalan Injec... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | NCT00361140 | Myelodysplastic... Myeloproliferat... Leukemia, Lymph... Myeloma Lymphoma | Busulfan Fludarabine | 16 Years - 65 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation | NCT01203020 | Hodgkin's Lymph... Non-Hodgkin's L... | Busulfan Fludarabine | 18 Years - 70 Years | West Virginia University | |
| Allogeneic Stem Cell Transplant for CLL | NCT01629511 | Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom... | Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | NCT00005940 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... | iodine I 131 mo... busulfan cyclophosphamid... allogeneic bone... allogeneic hema... peripheral bloo... cyclosporine methotrexate laboratory biom... | 16 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission | NCT00305708 | Congenital Ameg... Diamond-blackfa... Fanconi Anemia Leukemia Severe Congenit... Thrombocytopeni... | anti-thymocyte ... busulfan fludarabine pho... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera... | - 17 Years | University of California, San Francisco | |
| BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma | NCT03794167 | Non-hodgkin Lym... | Busulfan Cyclophosphamid... Etoposide Melphalan | 18 Years - 65 Years | Soonchunhyang University Hospital | |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01707004 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... | decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom... | 18 Years - 75 Years | University of Wisconsin, Madison | |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide | NCT00800839 | Hematologic Dis... Leukemia Lymphoma Myeloma | Busulfan Fludarabine Cyclophosphamid... | 6 Months - 75 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma | NCT00030719 | Neuroblastoma | filgrastim monoclonal anti... busulfan carboplatin cyclophosphamid... etoposide isotretinoin melphalan vincristine sul... bone marrow abl... conventional su... peripheral bloo... radiation thera... | 1 Year - 20 Years | National Cancer Institute (NCI) | |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome | NCT00024050 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo... | - 65 Years | Fred Hutchinson Cancer Center | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | NCT00534469 | Leukemia | aldesleukin filgrastim busulfan cytarabine etoposide idarubicin autologous hema... bone marrow tra... peripheral bloo... total-body irra... | 16 Years - 60 Years | City of Hope Medical Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies | NCT01247701 | Myeloid Hematol... | Busulfan Cyclophosphamid... Fludarabine Cord Blood Stem... | - 17 Years | Baylor College of Medicine | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma | NCT00004088 | Multiple Myelom... | filgrastim recombinant int... busulfan cyclophosphamid... melphalan pamidronate dis... thalidomide peripheral bloo... | - 65 Years | City of Hope Medical Center | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Study in Localized and Disseminated Ewing Sarcoma | NCT00987636 | Ewing's Sarcoma | Zoledronic acid Busulfan Treosulfan | 48 Months - 50 Years | University Hospital Muenster | |
| IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | NCT00469144 | Myelodysplastic... Leukemia Acute Myeloid L... | Busulfan Fludarabine | - 65 Years | M.D. Anderson Cancer Center | |
| Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | NCT00446173 | Leukemia | Busulfan Cyclophosphamid... G-CSF GM-CSF | 21 Years - 65 Years | M.D. Anderson Cancer Center | |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | NCT01168219 | Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... de Novo Myelody... Myelodysplastic... Myelodysplastic... Recurrent Adult... Secondary Myelo... | Allogeneic Hema... Anti-Thymocyte ... Azacitidine Busulfan Fludarabine Pho... Laboratory Biom... Methotrexate Pharmacological... Tacrolimus | 18 Years - 74 Years | National Cancer Institute (NCI) | |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | NCT01119066 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Multiple Myelom... | total body irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine Clofarabine (CliniMACS) T-c... | - 69 Years | Memorial Sloan Kettering Cancer Center | |
| Autologous Transplantation for Chronic Myelogenous Leukemia | NCT01003054 | Chronic Myeloge... | Busulfan Cyclophosphamid... Imatinib Mesyla... Autologous Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia | NCT00623935 | Acute Myelogeno... | Fludarabine Busulfan Total Body Irra... Stem Cell Trans... | 55 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
